Outcome attributes regarding effectiveness and adverse effects are most often included within discrete choice experiments in cancer treatment, and are often considered the most important by patients.

Process and cost attributes, in contrast, are included less often but are still of importance in most studies.

Clinicians and decision makers should be aware that patients value not only the outcome but also process and cost attributes, and aligning care with the patients’ preferences could lead to improved adherence to treatment and therefore greater efficiency.